Emergent Biosolutions Inc (NYSE: EBS) is 281.25% higher on its value in year-to-date trading and has touched a low of $1.42 and a high of $15.10 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EBS stock was last observed hovering at around $9.43 in the last trading session, with the day’s loss setting it -0.28%.
Currently trading at $9.15, the stock is -6.17% and -1.48% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing -2.97% at the moment leaves the stock 34.01% off its SMA200. EBS registered 281.25% gain for a year compared to 6-month gain of 46.17%. The firm has a 50-day simple moving average (SMA 50) of $9.223 and a 200-day simple moving average (SMA200) of $6.7955.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.12% loss in the last 1 month and extending the period to 3 months gives it a 21.68%, and is -9.50% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.17% over the week and 8.24% over the month.
Emergent Biosolutions Inc (EBS) has around 1600 employees, a market worth around $495.79M and $1.13B in sales. Fwd P/E is 5.24. Profit margin for the company is -18.55%. Distance from 52-week low is 544.37% and -39.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.68%).
The EPS is expected to grow by 82.99% this year
178.0 institutions hold shares in Emergent Biosolutions Inc (EBS), with institutional investors hold 61.19% of the company’s shares. The shares outstanding are 54.10M, and float is at 52.02M with Short Float at 13.10%. Institutions hold 59.91% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 3.84 million shares valued at $26.18 million. The investor’s holdings represent 7.3551 of the EBS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 3.67 million shares valued at $25.0 million to account for 7.0234 of the shares outstanding. The other top investors are CHARLES SCHWAB INVESTMENT MANAGEMENT INC which holds 3.17 million shares representing 6.0656 and valued at over $21.59 million, while MORGAN STANLEY holds 2.3796 of the shares totaling 1.24 million with a market value of $8.47 million.
Emergent Biosolutions Inc (EBS) Insider Activity
The most recent transaction is an insider sale by DeGolyer Donald W, the company’s Director. SEC filings show that DeGolyer Donald W sold 25,000 shares of the company’s common stock on Nov 12 ’24 at a price of $10.91 per share for a total of $0.27 million. Following the sale, the insider now owns 0.11 million shares.
Emergent Biosolutions Inc disclosed in a document filed with the SEC on Nov 11 ’24 that White Marvin L (Director) sold a total of 14,287 shares of the company’s common stock. The trade occurred on Nov 11 ’24 and was made at $11.97 per share for $0.17 million. Following the transaction, the insider now directly holds 54092.0 shares of the EBS stock.
Still, SEC filings show that on Nov 12 ’24, DeGolyer Donald W (Director) Proposed Sale 25,000 shares at an average price of $11.77 for $0.29 million. The insider now directly holds shares of Emergent Biosolutions Inc (EBS).
